AstraZeneca (AZN) Given “Hold” Rating at Shore Capital

AstraZeneca (LON:AZN)‘s stock had its “hold” rating restated by equities research analysts at Shore Capital in a research report issued on Friday.

AZN has been the topic of a number of other reports. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Thursday, July 26th. Deutsche Bank reaffirmed a “buy” rating and set a GBX 6,000 ($78.16) target price on shares of AstraZeneca in a research report on Friday, July 27th. UBS Group set a GBX 4,550 ($59.27) target price on AstraZeneca and gave the stock a “neutral” rating in a research report on Friday, May 18th. Liberum Capital reaffirmed a “hold” rating on shares of AstraZeneca in a research report on Friday, May 18th. Finally, Sanford C. Bernstein raised AstraZeneca to an “outperform” rating and boosted their target price for the stock from GBX 5,673 ($73.90) to GBX 6,026 ($78.49) in a research report on Monday, May 21st. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of GBX 5,689.45 ($74.11).

AZN opened at GBX 5,645 ($73.53) on Friday. AstraZeneca has a one year low of GBX 4,260 ($55.49) and a one year high of GBX 5,520 ($71.90).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

See Also: Outstanding Shares and The Effect on Share Price

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit